Johnson & Johnson (NYSE:JNJ) Stake Decreased by Van Cleef Asset Management Inc

Van Cleef Asset Management Inc decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,063 shares of the company’s stock after selling 328 shares during the period. Johnson & Johnson accounts for about 1.7% of Van Cleef Asset Management Inc’s investment portfolio, making the stock its 16th largest holding. Van Cleef Asset Management Inc’s holdings in Johnson & Johnson were worth $11,922,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. LaFleur & Godfrey LLC raised its holdings in Johnson & Johnson by 4.9% during the third quarter. LaFleur & Godfrey LLC now owns 118,918 shares of the company’s stock worth $18,521,000 after purchasing an additional 5,585 shares in the last quarter. Hanlon Investment Management Inc. raised its holdings in Johnson & Johnson by 46.3% during the third quarter. Hanlon Investment Management Inc. now owns 2,081 shares of the company’s stock worth $324,000 after purchasing an additional 659 shares in the last quarter. Kessler Investment Group LLC increased its holdings in shares of Johnson & Johnson by 1.9% in the third quarter. Kessler Investment Group LLC now owns 52,455 shares of the company’s stock valued at $8,170,000 after buying an additional 974 shares in the last quarter. Proficio Capital Partners LLC increased its holdings in shares of Johnson & Johnson by 1.5% in the third quarter. Proficio Capital Partners LLC now owns 21,097 shares of the company’s stock valued at $3,286,000 after buying an additional 306 shares in the last quarter. Finally, Capital Advisory Group Advisory Services LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at $1,260,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on JNJ. Morgan Stanley dropped their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Raymond James upped their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, April 15th. Finally, Bank of America lowered their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Trading Down 1.5 %

Johnson & Johnson stock opened at $144.61 on Wednesday. The company’s fifty day simple moving average is $154.80 and its 200-day simple moving average is $155.14. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The stock has a market cap of $348.48 billion, a P/E ratio of 9.02, a P/E/G ratio of 2.42 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same period in the previous year, the company posted $2.68 EPS. Johnson & Johnson’s revenue was up 2.3% on a year-over-year basis. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.43%. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson’s payout ratio is currently 29.68%.

Insider Buying and Selling

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.